Beyond Air (NASDAQ:XAIR) Posts Earnings Results, Beats Expectations By $0.12 EPS

Beyond Air (NASDAQ:XAIR) released its quarterly earnings data on Tuesday. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.12, Yahoo Finance reports. The company had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.72 million. Beyond Air had a negative return on equity of 203.12% and a negative net margin of 5,197.76%. During the same period last year, the business posted ($0.45) EPS.

Beyond Air Trading Down 5.9 %

Shares of NASDAQ XAIR traded down $0.03 during mid-day trading on Wednesday, reaching $0.48. 535,575 shares of the company’s stock were exchanged, compared to its average volume of 528,259. The firm has a market capitalization of $21.80 million, a price-to-earnings ratio of -0.28 and a beta of -0.10. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.61 and a current ratio of 3.80. Beyond Air has a 52-week low of $0.47 and a 52-week high of $3.90. The company’s 50-day moving average is $0.83 and its 200-day moving average is $1.29.

Wall Street Analysts Forecast Growth

XAIR has been the topic of several analyst reports. BTIG Research lowered shares of Beyond Air from a “buy” rating to a “neutral” rating in a report on Tuesday, June 25th. Piper Sandler decreased their target price on Beyond Air from $3.50 to $1.00 and set an “overweight” rating for the company in a report on Wednesday. Finally, Truist Financial lowered their price target on shares of Beyond Air from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th.

About Beyond Air

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.